Advances in disease biology
AL amyloidosis
CAR T cells in myeloma
Choice of therapy for non-transplant eligible patients
Guidelines in specific clinical situations
Immunotherapy
Minimal residual disease
Ongoing clinical trials and future trials
Options for refractory myeloma
Outcome prediction
Practical guidelines for the practicing physician
Smoldering myeloma and MGUS
Special session for patients’ advocacy group
Treatment guidelines for young patients
Treatment of relapse
Waldenstrom macroglobulinemia